  0086-18989305995        sales@mosinterchem.com
You are here: Home / Products-list / Pharmaceutical Chemicals API / Circulatory System Drugs API / Urokinase CAS 9039-53-6 Tissuecultureurokinase

PRODUCTS DETAILS

Urokinase CAS 9039-53-6 Tissuecultureurokinase

Model: CAS:9039-53-6
Place of Origin: Shandong,China (Mainland)
Brand: MOSINTER
Storage condiion: 2-8°C
Form: powder
Color: white

  • 9039-53-6
  • MOSINTER
  • 9039-53-6
Product Description

Payment & Shipping Terms

Supply Capacity

Payment Terms:

T/T, WU

Production Capacity:

500Ton/year

Min. Order:

1 Gram

Packing:

according to the customer's requirements 

Means of Transport:

Ocean, Air, Land

Delivery Date:

7 days

 

Urokinase ( CAS: 9039-53-6)

Item

Index

Molecular   Formula

C21H25BrN2O3

Specification

CP/USP/EP

Appearance

White powder

Storage Condition

2-8°C

 

Urokinase (trade name Abbokinase), also called urokinase-type plasminogen activator (uPA), is a serine protease (EC3.4.21.73). It was discovered in 1947 by McFarlane. Urokinase was originally isolated from human urine, but is present in several physiological locations, such as blood stream and the extracellular matrix. The primary physiological substrate is plasminogen, which is an inactive form (zymogen) of the serine protease plasmin. Activation of plasmin triggers a proteolysis cascade that, depending on the physiological environment, participates in thrombolysis orextracellular matrix degradation. This links urokinase to vascular diseases and cancer.

Molecular characteristics

Urokinase is a 411-residue protein, consisting of three domains: the serine protease domain, the kringle domain, and thegrowth factor domain. Urokinase is synthesized as a zymogen form (prourokinase or single-chain urokinase), and is activated by proteolytic cleavage between Lys158 and Ile159. The two resulting chains are kept together by a disulfidebond.

Urokinase and cancer

Elevated expression levels of urokinase and several other components of the plasminogen activation system are found to be correlated with tumor malignancy. It is believed that the tissue degradation following plasminogen activation facilitates tissue invasion and, thus, contributes to metastasis. This makes urokinase an attractive drug target, and, so, inhibitors have been sought to be used as anticancer agents. However, incompatibilities between the human and murinesystems hamper clinical evaluation of these agents. Through its interaction with the urokinase receptor, urokinase affects several other aspects of cancer biology such as cells adhesion, migration, and cellular mitotic pathways.

As of December 7, 2012 Mesupron®, a small molecule serine protease inhibitor developed by the WILEX pharmaceutical company, has completed phase II trials. Mesupron appears to be safe when combined with chemotherapeutic drug Capecitabine for the progression-free survival in human breast cancer.

 


PRODUCT INQUIRY
If you would like to have a question then get in touch today, we are ready to assist 24/7.
We welcome your cooperation and we will develop with you.
Factory-direct Connectivity Solutions.
High quality, Competitive Price.
Custom-tailored solutions.
Problem-solving approach.

OUR PRODUCT/SERVICE

MOSINTER GROUP was established in 2004. The main office is located in Ningbo, China. The production are located in Zhejiang Province, Jiangsu Province and Shandong Province in China. Specializing in the production and marketing of chemical products, MOSINTER GROUP has excellent production equipment and a high-performing sales team as well as advanced manufacturing technique, comprehensive quality management system and modernized testing methods.

QUICK LINK

CONTACT INFO

  0086-18989305995
 0086-574-88212215
  sales@mosinterchem.com
  YinXianDaDao 1357, Guangbo Center Office 2003, Ningbo, Zhejiang, China
 forwardcy
 0086-18989305995
 0086-18989305995
Copyright  2020 Mosinter Group Limited All rights reserved.